BBIOHIGH SIGNALFINANCIAL10-K

BBIO shows concerning financial deterioration with substantially higher current liabilities, widening losses, and a significantly expanded cost structure despite improved operating cash flow.

The company's current liabilities substantially increased to $288M while cash declined to $570M, creating potential liquidity pressure. The dramatic expansion in SG&A expenses suggests significant commercial investments, likely related to their expanded trademark registrations across multiple jurisdictions for Attruby/Beyonttra, but this is straining profitability in the near term.

Comparing 2026-02-24 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

BBIO's financial profile shows mixed signals with concerning liability growth and cost expansion offset by some operational improvements. Current liabilities substantially increased while cash reserves declined 16%, creating a tighter liquidity position. However, the company showed modest improvement in operating cash flow and operating income, even as net losses widened due to the substantially higher SG&A spending, suggesting significant commercial investment activity.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+86.5%
$154.4M→$288.0M

Current liabilities surged 86.5% — significant near-term obligations; verify ability to meet short-term debt.

SG&A Expense
P&L
+83.9%
$288.9M→$531.2M

SG&A up 83.9% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Stockholders Equity
Balance Sheet
-42.1%
-$1.5B→-$2.1B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-35.3%
-$535.8M→-$724.9M

Net income declined 35.3% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+26.7%
$2.4B→$3.0B

Liabilities increased 26.7% — monitor debt-to-equity ratio and interest coverage.

Cash & Equivalents
Balance Sheet
-16.3%
$681.1M→$570.1M

Cash decreased 16.3% — monitor burn rate and upcoming capital needs.

Operating Cash Flow
Cash Flow
+14.4%
-$520.7M→-$445.9M

Operating cash flow grew 14.4% — strong conversion of earnings to cash, healthy business fundamentals.

Dividends Paid
Cash Flow
-13.4%
$1.2M→$997K

Dividend reduced 13.4% — monitor management commentary on capital allocation priorities.

Operating Income
P&L
+11.7%
-$593.0M→-$523.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

R&D Expense
P&L
-10.8%
$506.5M→$452.0M

R&D spending cut 10.8% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-20
ADDED
On February 12, 2026, there were 193,862,871 shares of the registrant s Common Stock issued and outstanding.
BRIDGEBIO and ATTRUBY are our registered trademarks in the United States ( U.S.
BRIDGEBIO, ATTRUBY and BEYONTTRA are our registered trademarks in the European Union ( EU ), the United Kingdom ( UK ) and Japan.
Otherwise, including in discussions of our achondroplasia, autosomal dominant hypocalcemia type 1 (ADH1), and limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) development programs, we refer to our product candidates by their scientific (or generic) name or BridgeBio Pharma ( BBP ) developmental designation.
When referring to our commercial product that has been approved in (i) the U.S.
+7 more — sign up free →
REMOVED
On February 13, 2025, there were 190,188,626 shares of the registrant s Common Stock issued and outstanding.
BRIDGEBIO, ATTRUBY and BEYONTTRA are our registered trademarks in the European Union.
Otherwise, including in discussions of our achondroplasia, ADH1 and LGMD2I/R9 development programs, we refer to our product candidates by their scientific (or generic) name or BridgeBio Pharma ( BBP ) developmental designation.
Where referring to our commercial product that has been approved in both the United States and European Union, we use both names Attruby TM /Beyonttra TM e.g., Our commercial organization focuses on supporting the appropriate use of ATTRUBY and BEYONTTRA in the markets where this product has been approved.
iii RISK FACTOR SUMMARY Below is a summary of the principal factors that make an investment in our common stock speculative or risky.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →